Browse > Article

Retardation of axonal regeneration in the sciatic nerve after injury in streptozotocin-induced diabetes  

Hwang, Jinyeon (College of Korean medicine, Daejeon University)
Kim, Ki-Joong (College of Korean medicine, Daejeon University)
Namgung, Uk (College of Korean medicine, Daejeon University)
Publication Information
Journal of Haehwa Medicine / v.29, no.1, 2020 , pp. 18-25 More about this Journal
Abstract
Objective: The goal of this study is to investigate whether peripheral axonal regeneration is affected by diabetes in experimental animals. Method: Sprague Dawely rat was injected with 45~50 mg/kg of streptozotocin (STZ) to generate an animal model of diabetes. Three months after STZ injection, sciatic nerve (2 cm length) was removed and the same length of nerve segments from STZ-injected animal or from control animal (CTL) was transplanted into STZ-injected animals (STZ-STZ and STZ-CTL respectively). Similarly, sciatic nerve segments from STZ-injected animal or from control animal were grafted into the control animals (CTL-STZ and CTL-CTL respectively). All animals were sacrificed 2 weeks after transplantation. Sciatic nerve sections were prepared and subjected to immunofluorescence staining analysis. Results: Immunofluorescence staining for NF-200 showed that distal elongation of regenerating axons reached 40~80% of proximal neve in both CTL-STZ and CTL-CTL groups. However, distal elongation in both STZ-STZ and STZ-CTL groups were 20~60% of proximal nerve. Furthermore, measurement of axonal regeneration after immuno-staining with SCG10 showed that the scores of distal elongation relative to proximal nerve were 50~90% in CTL-CTL and CTL-STZ groups and 10-60% in STZ-CTL and STZ-STZ. Conclusions: Our data showed that the levels of axonal regeneration were not affected irrespective of whether they were from STZ- or CTL graft, but were greatly reduced when the nerves were transplanted into the STZ host.
Keywords
Diabetes; Axonal regeneration; transplantation; Streptozotocin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013 Oct 24;5(1):57.   DOI
2 Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006 May;55(5):1463-9.   DOI
3 Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011 Sep 13;7(10):573-83.   DOI
4 Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154.   DOI
5 Biessels GJ, Bril V, Calcutt NA, Cameron NE, Cotter MA, Dobrowsky R, et al. animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst. 2014 Jun;19(2):77-87.   DOI
6 Malik RA, Tesfaye S, Newrick PG, Walker D, Rajbhandari SM, Siddique I et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. 2005 Mar;48(3):578-85.   DOI
7 Lindberger M, Schroder HD, Schultzberg M, Kristensson K, Persson A, Ostman J et al. Nerve fibre studies in skin biopsies in peripheral neuropathies. I. Immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci. 1989 Nov;93(2-3):289-96.   DOI
8 Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93.   DOI
9 Kumar S, Dikshit M. Metabolic Insight of Neutrophils in Health and Disease. Front Immunol. 2019 Sep 20;10:2099.   DOI
10 Laddha AP, Kulkarni YA. Tannins and vascular complications of Diabetes: An update. Phytomedicine. 2019 Mar 15;56:229-245.   DOI
11 Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012 Jun;11(6):521-34.   DOI
12 Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology. 2007 Feb;148(2):548-58.   DOI
13 Duran-Jimenez B, Dobler D, Moffatt S, Rabbani N, Streuli CH, Thornalley PJ, Tomlinson DR, Gardiner NJ. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes. 2009 Dec;58(12):2893-903.   DOI
14 Almaguel FG, Liu JW, Pacheco FJ, De Leon D, Casiano CA, De Leon M. Lipotoxicity-mediated cell dysfunction and death involve lysosomal membrane permeabilization and cathepsin L activity. Brain Res. 2010 Mar 8;1318:133-43.   DOI
15 Tsintzas K, Chokkalingam K, Jewell K, Norton L, Macdonald IA, Constantin-Teodosiu D. Elevated free fatty acids attenuate the insulin-induced suppression of PDK4 gene expression in human skeletal muscle: potential role of intramuscular long-chain acyl-coenzyme A. J Clin Endocrinol Metab. 2007 Oct;92(10):3967-72   DOI
16 Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes. 2009 Oct;58(10):2376-85.   DOI
17 Arnold R, Kwai N, Lin CS, Poynten AM, Kiernan MC, Krishnan AV. Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes Metab Res Rev. 2013 Jan;29(1):53-9.   DOI
18 Sung JY, Tani J, Chang TS, Lin CS., Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS One. 2017 Feb 9;12(2):e0171223.   DOI
19 Misawa S, Sakurai K, Shibuya K, Isose S, Kanai K, Ogino J et al., Neuropathic pain is associated with increased nodal persistent Na(+) currents in human diabetic neuropathy. J Peripher Nerv Syst. 2009 Dec;14(4):279-84.   DOI
20 Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest. 1988 Feb;81(2):349-64.   DOI
21 Painter MW, Brosius Lutz A, Cheng YC, Latremoliere A, Duong K, Miller CM, et al. Diminished Schwann cell repair responses underlie age-associated impaired axonal regeneration. Neuron. 2014 Jul 16;83(2):331-343.   DOI
22 Ozon S, Maucuer A, Sobel A. The stathmin family -- molecular and biological characterization of novel mammalian proteins expressed in the nervous system. Eur J Biochem. 1997 Sep 15;248(3):794-806.   DOI
23 Riederer BM, Pellier V, Antonsson B, Di Paolo G, Stimpson SA, Lutjens R et al. Regulation of microtubule dynamics by the neuronal growth-associated protein SCG10. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):741-5.   DOI
24 Wang J, Shan C, Cao W, Zhang C, Teng J, Chen J. SCG10 promotes non-amyloidogenic processing of amyloid precursor protein by facilitating its trafficking to the cell surface. Hum Mol Genet. 2013 Dec 15;22(24):4888-900.   DOI
25 Morii H, Shiraishi-Yamaguchi Y, Mori N. SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. J Neurobiol. 2006 Sep 1;66(10):1101-14.   DOI
26 Sugiura Y, Mori N. SCG10 expresses growth-associated manner in developing rat brain, but shows a different pattern to p19/stathmin or GAP-43. Brain Res Dev Brain Res. 1995 Dec 21;90(1-2):73-91.   DOI
27 Tararuk T, Ostman N, Li W, Bjorkblom B, Padzik A, Zdrojewska J et al. JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol. 2006 Apr 24;173(2):265-77.   DOI
28 Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S et al. SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):E3696-705.   DOI
29 Chen ZL, Yu WM, Strickland S. Peripheral regeneration. Annu Rev Neurosci. 2007;30:209-33.   DOI
30 Eckersley L, Ansselin AD, Tomlinson DR. Effects of experimental diabetes on axonal and Schwann cell changes in sciatic nerve isografts. Brain Res Mol Brain Res. 2001 Aug 15;92(1-2):128-37.   DOI
31 Goncalves NP, Mohseni S, El Soury M, Ulrichsen M, Richner M, Xiao J et al. Peripheral Nerve Regeneration Is Independent From Schwann Cell p75(NTR) Expression. Front Cell Neurosci. 2019 May 29;13:235.   DOI
32 Petratos S, Butzkueven H, Shipham K, Cooper H, Bucci T, Reid K et al. Schwann cell apoptosis in the postnatal axotomized sciatic nerve is mediated via NGF through the low-affinity neurotrophin receptor. J Neuropathol Exp Neurol. 2003 Apr;62(4):398-411.   DOI
33 Saika F, Kiguchi N, Matsuzaki S, Kobayashi D, Kishioka S. Inflammatory Macrophages in the Sciatic Nerves Facilitate Neuropathic Pain Associated with Type 2 Diabetes Mellitus. J Pharmacol Exp Ther. 2019 Mar;368(3):535-544.   DOI
34 Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol. 2006 Oct 30;72(9):1102-13.   DOI
35 Dodda D, Ciddi V. Plants used in the management of diabetic complications. Indian J Pharm Sci. 2014;76(2):97-106.
36 Beeve AT, Brazill JM, Scheller EL. Peripheral Neuropathy as a Component of Skeletal Disease in Diabetes. Curr Osteoporos Rep. 209 Aug 7.
37 Tang W, Chen X, Liu H, Lv Q, Zou J, Shi Y et al. Expression of Nrf2 Promotes Schwann Cell-Mediated Sciatic Nerve Recovery in Diabetic Peripheral Neuropathy. Cell Physiol Biochem. 2018;46(5):1879-1894.   DOI
38 Kim KJ, Namgung U, Cho CS. Protective Effects of Bogijetong Decoction and Its Selected Formula on Neuropathic Insults in Streptozotocin-Induced Diabetic Animals. Evid Based Complement Alternat Med. 2017;2017:4296318.
39 Kim KJ, Namgung U. Facilitating effects of Buyang Huanwu decoction on axonal regeneration after peripheral nerve transection. J Ethnopharmacol. 2018 Mar 1;213:56-64.   DOI